ENTITY
Shanghai Junshi Biosciences

Shanghai Junshi Biosciences (1877 HK)

209
Analysis
Health CareChina
Shanghai Junshi Biosciences Co., Ltd. operates as a biopharmaceutical company. The Company develops and sells small molecule drugs, antibody drug conjugates, and other products. Shanghai Junshi Biosciences markets its products worldwide.
more
Refresh
bearishEvergrande Auto
28 Sep 2020 16:36

Evergrande Auto (708 HK): EGM Ahead Of Star Market Listing

This week in StubWorld ... Three days after raising HK$4bn via a top-up placement, Evergrande Auto (708 HK) ("EA") also officially known...

Logo
284 Views
Share
17 Sep 2020 01:38

JHBP Holdings (Genor Biopharma) IPO Initiation: Hunting for a Cure

$ Genor Biopharma is a biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. Its drug candidates...

Logo
442 Views
Share
18 Sep 2019 15:37

Shanghai Henlius (复宏汉霖) IPO: Take-Aways from Peer PD-1 Sales in China

We have gathered the sales data for PD-1 products from four players in China for the first half of 2019. As its anti-PD-1 monoclonal antibody,...

Logo
511 Views
Share
11 Sep 2019 15:34

Shanghai Henlius Biotech IPO: Valuation Prescribed at Low-End

Shanghai Henlius Biotech (2696 HK) is a biopharmaceutical company and a non-wholly owned subsidiary of Shanghai Fosun Pharmaceutical (Group) (2196...

Logo
510 Views
Share
bullishAlphamab Co Ltd
30 Jul 2019 17:39

Alphamab IPO: Interims from Merck's Breast Cancer Trial Bodes Well for Alphamab and Junshi

Last night, Merck & Co Inc. (MRK US) announced that its Keytruda hits primary endpoint in Phase III (KEYNOTE-522) clinical trial in the...

Logo
561 Views
Share
x